Last reviewed · How we verify
NCT06355219: M6
Macrovascular and Microvascular Morbidity and Mortality After Metabolic Surgery Versus Medicines
trial in Type 2 Diabetes Mellitus in 3,932 participants. Completed in 20 May 2024.
31 December 2022
Quick facts
| Lead sponsor | Ali Aminian |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 3,932 |
| Start date | 1 January 2010 |
| Primary completion | 31 December 2022 |
| Estimated completion | 20 May 2024 |
Conditions studied
- Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →
- Obesity — all drugs for Obesity →
- Microvascular Disease — all drugs for Microvascular Disease →
- Macrovascular Disease — all drugs for Macrovascular Disease →
Sponsor
Ali Aminian — full company profile →
Who can join
Adults 18 to 75, any sex, with Type 2 Diabetes Mellitus or Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to compare the impact of metabolic surgery and a class of anti-diabetes medications (Glucagon-like peptide-1 receptor agonists,GLP-1 RAs) on occurrence of diseases involving small and large vessels such as heart disease, kidney disease, and disease of the retina (a part of the eye), as well as deaths.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06355219
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 2 Diabetes Mellitus
Currently open trials in the same condition.
- NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
- NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
- NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
- NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
- NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting
Other Ali Aminian trials
Trials by the same sponsor.
- NCT07027969 — Metabolic Surgery for Atrial Fibrillation Elimination · Phase 4 · not yet recruiting
- NCT06803888 — Bariatric Surgery vs. Semaglutide vs. Tirzepatide · Phase 4 · recruiting
- NCT06374875 — Fibrosis Lessens After Metabolic Surgery · Phase 4 · recruiting
- NCT02328599 — Alliance of Randomized Trials of Medicine vs Metabolic Surgery in Type 2 Diabetes · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06355219 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ali Aminian
- Last refreshed: 21 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06355219.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing